4 August 2021
\n \n \n \nProceeds to support expansion and advancement of PepGen\u2019s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
\n \n\n \n \n22 July 2021
\n \n \n \nAfter a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
\n \n\n \n \n24 June 2021
\n \n \n \nMediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
\n \n\n \n \n17 June 2021
\n \n \n \nThe funding will be used to advance the development of Ochre Bio\u2019s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
\n \n\n \n \n13 June 2021
\n \n \n \nOXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
\n \n\n \n \n10 June 2021
\n \n \n \nAlchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
\n \n\n \n \n31 May 2021
\n \n \n \nMoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
\n \n\n \n \n29 April 2021
\n \n \n \nAlchemab Therapeutics, the antibody therapeutic start-up backed by SV Health Investors, has graduated from the BioEscalator after 18 months in the Innovation Labs.
\n \n\n \n \n26 April 2021
\n \n \n \nMoA Technology, a spin-out company from Oxford University\u2019s Department of Plant Sciences, has secured an additional \u00a35M funding for its series A round to support the expansion and acceleration of its discovery programme.
\n \n\n \n \n16 April 2021
\n \n \n \nThe biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
\n \n\n \n \n23 March 2021
\n \n \n \n\n \n \n10 March 2021
\n \n \n \nAccunea is pioneering the next generation of continuous, real-time organ function monitoring to ensure every transplant counts.
\n \n\n \n \n26 February 2021
\n \n \n \nBioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.
\n \n\n \n \n12 January 2021
\n \n \n \nThe partnership deal, worth over \u20ac876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
\n \n\n \n \n6 January 2021
\n \n \n \nTheolytics raises \u00a35M ($6.8M) Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies.
\n \n\n \n \n9 December 2020
\n \n \n \nEnara Bio relocates to The Oxford Science Park\u2019s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies.
\n \n\n \n \n9 December 2020
\n \n \n \nRA Capital Management leads $45M Series A financing for PepGen\u2019s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round.
\n \n\n \n \n28 October 2020
\n \n \n \nWe are excited to announce that one of our resident companies, Base Genomics, has been acquired by Exact Sciences for $410 million. The acquisition will undoubtedly further propel Base Genomics' groundbreaking technology alongside Exact Sciences' existing expertise, ultimately enhancing cancer diagnostics.
\n \n\n \n \n5 October 2020
\n \n \n \nNovel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.
\n \n\n \n \n30 September 2020
\n \n \n \nAlchemab announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence.
\n \n\n \n \n